Ovarian Neoplasms: all 2,757 studies
Page 27 of 28. Open to participants first (735), then studies with results posted, then the rest; newest registration first within each.
- Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerCompletedNCT00138242Phase 2
- Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian CancerTerminatedNCT00137865Phase 1
- An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing RadiationCompletedNCT00132704
- Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma PatientsCompletedNCT00127920Phase 2
- Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low IncidenceCompletedNCT00123773Phase 2
- Study of Motexafin Gadolinium and Docetaxel for Advanced CancerCompletedNCT00120939Phase 1
- Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian CancerCompletedNCT00113789Phase 2
- OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206CompletedNCT00112086Phase 2
- Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based ChemotherapyCompletedNCT00109096Phase 2
- Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune ResponseCompletedNCT00103545Phase 1/2
- TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian CancerCompletedNCT00102973Phase 3
- Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian CancerTerminatedNCT00102622Phase 1
- Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian CancerCompletedNCT00102414Phase 3
- Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian CancerCompletedNCT00102375Phase 3
- Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal CancerCompletedNCT00101257Phase 1
- Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the OvariesCompletedNCT00098800Not applicable
- Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian CancerCompletedNCT00097409Phase 2
- A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has FailedCompletedNCT00097019Phase 2
- CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00096239Phase 2
- Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00091377Phase 1/2
- Acupuncture for Women's Health ConditionsCompletedNCT00090389Phase 1
- EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
- Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedNCT00087087Phase 2
- Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer TreatmentTerminatedNCT00086632Phase 2
- Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic OophorectomyWithdrawnNCT00084370Not applicable
- Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 LevelsCompletedNCT00083928Phase 2
- A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal CarcinomaTerminatedNCT00082212Phase 2
- CA-125 in Screening Patients at High Risk for Ovarian CancerWithdrawnNCT00080639
- Study of Motexafin Gadolinium and Docetaxel for Advanced Solid TumorsCompletedNCT00080041Phase 1
- Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube CancerCompletedNCT00074867Phase 2
- A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian CancerCompletedNCT00073541Phase 2
- UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00072267Phase 2
- Phase II CT-2103/Carboplatin in Ovarian CancerCompletedNCT00069901Phase 2
- Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube CancerCompletedNCT00066456Phase 1
- Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal CancerCompletedNCT00061308Phase 2
- Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube CancerCompletedNCT00060359Phase 1
- PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube CancerCompletedNCT00059618Phase 1
- CA125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal WomenCompletedNCT00058032Not applicable
- TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian CancerCompletedNCT00057720Phase 3
- A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid MalignanciesStatus unknownNCT00057395Phase 1/2
- Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal CancerTerminatedNCT00055432Phase 2
- S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerTerminatedNCT00053833Phase 2
- Research Study in Patients With Advanced Ovarian Epithelial CancerWithdrawnNCT00053235
- Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube CancerCompletedNCT00052468Phase 3
- TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian CancerCompletedNCT00052065Phase 1/2
- TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian CancerCompletedNCT00051948Phase 1/2
- Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian CancerTerminatedNCT00051584Phase 2
- A Study of Trabectedin in Patients With Advanced Ovarian CancerCompletedNCT00050414Phase 2
- Clinical Trial for Ovarian Cancer (OvaRex®)TerminatedNCT00050375Phase 3
- Gefitinib in Treating Patients With Cervical CancerCompletedNCT00049556Phase 2
- Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian CancerCompletedNCT00046800Phase 2
- Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic RiskCompletedNCT00043472
- Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.Status unknownNCT00043446Phase 2
- S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian CancerCompletedNCT00043082Phase 3
- Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian CancerTerminatedNCT00042952Phase 2
- Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian CancerCompletedNCT00040222
- Massage Therapy for Cancer-Related FatigueCompletedNCT00039793Phase 2
- Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential TumorCompletedNCT00039585Phase 2
- Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian CancerStatus unknownNCT00039559Not applicable
- Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian CancerCompletedNCT00038428Phase 2
- EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal CancerCompletedNCT00035100Phase 2
- Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian CarcinomaTerminatedNCT00034372Phase 2
- Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2CompletedNCT00034281Phase 1
- Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian CancerCompletedNCT00034151Phase 2
- A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial CarcinomaTerminatedNCT00034138Phase 1/2
- Screening Women at High Genetic Risk for Ovarian CancerCompletedNCT00033488Not applicable
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
- Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal CancerCompletedNCT00030706Phase 2
- Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00030446Phase 2
- Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00028912Phase 1
- Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00028743Phase 3
- S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian CancerTerminatedNCT00023634Phase 1
- TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00022347Phase 2
- Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian CancerStatus unknownNCT00021385Phase 2
- Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian CancerCompletedNCT00019916Phase 1/2
- Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal CancerCompletedNCT00019552Phase 2
- Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00019461Phase 2
- Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial CancerCompletedNCT00019136Phase 1
- Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal CancerStatus unknownNCT00017303Phase 2
- Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased RiskTerminatedNCT00017134Not applicable
- Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian CancerCompletedNCT00016224Phase 2
- ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00014690Phase 2
- Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial CancerCompletedNCT00010179Phase 2
- Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00006391Phase 1
- Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian CancerTerminatedNCT00006356Phase 3
- Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial CancerTerminatedNCT00006262Phase 2
- Nitrocamptothecin in Treating Patients With Advanced Ovarian CancerCompletedNCT00006230Phase 2
- SU5416 and Carboplatin to Treat Ovarian CancerCompletedNCT00006155Phase 1
- Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based ChemotherapyCompletedNCT00006028Phase 2
- LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian CancerCompletedNCT00005858Phase 1
- Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based ChemotherapyCompletedNCT00005836Phase 2
- Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian CancerCompletedNCT00005807Phase 1
- ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous TreatmentWithdrawnNCT00005645Phase 2
- Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial CancerTerminatedNCT00005612Phase 1/2
- Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial CancerCompletedNCT00005051Phase 2
- Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal CancerCompletedNCT00005046Phase 1
- Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerStatus unknownNCT00005025Phase 2
- Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerCompletedNCT00004934Phase 3
- High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During SurgeryCompletedNCT00004921Phase 3
- Effect of Chemotherapy Given Either by Mouth or by Infusion on the Quality of Life of Patients With Recurrent Ovarian Epithelial CancerCompletedNCT00004909